45results about How to "Good clinical application value" patented technology

The invention discloses the application of LncRNA-GAS5 in preparing a glaucoma diagnosis reagent and a glaucoma lesion diagnosis reagent kit. Through high-throughput sequencing and quantitative PCR validation, it is found that the LncRNA-GAS5 has a significant correlation with the occurrence of glaucoma. The LncRNA-GAS5 can be used for screening clinical glaucoma patients and providing a theoretical basis for early intervention in glaucoma.

The invention discloses a method for preparing Chinese traditional medicinal compound salvia miltiorrhiza preparation for curing cardiovascular and cerebrovascular diseases, comprising the following steps: choosing salvia miltiorrhiza crude medicaments; slicing or crashing the salvia miltiorrhiza crude medicaments into coarse particles; extracting with water for 2-4 times at 20-80 DEG C; adding 4-12 quantities of water respectively for extracting for 1-3 hours; choosing panax notoginseng crude medicaments; slicing or crashing the panax notoginseng crude medicaments into coarse particles; adding water for decoction and extraction for 2-4times; adding 4-12 quantities of water respectively for decoction and extraction for 1-3 hours; combining extract of salvia miltiorrhiza water and extract of panax notoginseng water; regulating pH to be 1-7; mixing uniformly, standing for 0.5-12 hours; filtering or centrifuging; attaching supernatant fluid through macroporous to a resin column; washing until the effluent liquid reduces sugar to be negative; abandoning the washing liquid; using 30-100% of ethanol for elution; collecting elution liquid; recycling ethanol from the elution liquid; concentrating and drying the ethanol to obtain the extract of salvia miltiorrhiza and panax notoginseng; adding borneol flakes and accessories for preparing tablets, capsules, soft capsules, oral solution, dripping pills, spraying agents or granules.

The invention relates to a recombination preparation method and an application of an Exendin-4 derivative with Exendin-4 activity. The molecular structural formula of the derivative is one of the following six forms of Exendin-4 (1-39)-Xaa40 (Seq ID No.2), Exendin-4 (1-39)-Xaa40-Xaa41 (Seq ID No.3), Exendin-4 (1-39)-Xaa40-Xaa41-Xaa42 (Seq ID No.4), Exendin-4 (1-30)-Xaa31-(Seq ID No.6), Exendin-4(1-30)-Xaa31-Xaa32 (Seq ID No.7) and Exendin-4 (1-30)-Xaa31-Xaa32-Xaa33 (Seq IN No.8), wherein Xaa40, Xaa41, Xaa42, Xaa31, Xaa32 and Xaa33 are respectively any one amino acid of Cys, Ala, Gly, His, Serand Thr. The derivative is prepared by a DNA recombination technology, has a longer half-life period than Exendin-4, is easy to purify with low cost, and is especially suitable to be used as an activecomponent of the medicament in the preparation of a medicament for treating diabetes.

The invention discloses an individualized 3D printing multifunctional artificial orbital implant and a preparation method thereof. The surface of the artificial orbital implant has a porous structure,the pores of the porous structure are circular pores, and the porous structure of the surface is arranged in a gradient manner, and the pores in the porous structure are arranged on the surface of the artificial orbital implant spaced apart; a special structure for fixing four extraocular muscles is arranged on the artificial orbital implant, the special structure consists of two elliptical holeswhich penetrate each other and are arranged close to each other, the preset sutures on the extraocular muscles pass through the two elliptical foramen and are knotted and fixed at the intersection of30 degree north latitude and 0 degree, 90 degree, 180 degree and 270 degree longitude respectively. The prosthetic orbital implant is printed directly by the digital model of the prosthetic orbital implant using 3D printing technology. The artificial orbital implant has high matching degree with the healthy eye and reduces the risk of exposure and infection after implantation of the orbital implant. The artificial orbital implant has good mobility and good simulation effect with individualized ophthalmic prosthesis, and has good clinical application value.

The invention discloses an HPR1 gene mutant, as well as relationship between the HPR1 gene mutant and autosomal dominant nonsyndromic deafness. The deafness-related mutation site is the nucleotide 547of the HPR1 gene coding region at which C mutates to G; and the mutation causes the amino acid 183 to mutate, after translation, from L to V (c. 547C > G, p. L183V). The invention discloses application of the HPR1 gene mutant for preparing a diagnostic reagent for deafness, as well as a diagnostic kit for deafness. By performing exome sequencing and animal experiment validation on family memberswith deafness, the invention discovers significant correlation between HPR1 and deafness, namely, the HPR1 is an important inducement of hereditary deafness; and thus, the HPR1 can be used for early clinical diagnosis of patients with deafness. Moreover, theoretical basis can be provided for early intervention and treatment on the deafness.

The invention relates to extract of the steroid saponin produced from the yam or the yam with the guilder leaf which has the character of containing the 80%-90% the steroid saponin in the percentage by weight. The intravenous fluid produced from the extract of the steroid saponin can not only dilate the coronary, depress the myocardial oxygen consumption, melt the thrombus, improve the myocardial ischemia and the microcirculation, amend the function of the vas endothelial cell, increase the blood stream of the brain, prevent the ischemia brain cell injury, but also drop the blood pressure, the blood fat, the blood sugar; at the same time, it has the function of resisting inflammation, ease pain, codein, preventing asthma, dispelling the myospasm, improving the immunity and resisting the allergy. So it can cure the cerebrovascular, the rheumatism and the disease of the respiratory system. The invention has the good clinic extended value because of the low dosage of the active ingredient, the efficacy, the effecting quick and the high bioavailability.

The invention discloses application of non-coding RNA molecule Lnc-DC in predicting drug resistance of tamoxifen in breast cancer as well as application of non-coding Lnc-RNA molecule Lnc-DC in preparing a detection agent for predicting the drug resistance of the tamoxifen in the breast cancer. The nucleotide sequence of the Lnc-DC is shown as SEQ ID NO.1. The invention also discloses primers or aprobe for predicting the drug resistance of the tamoxifen in the breast cancer and a method for improving the effect of predicting the tamoxifen for the breast cancer. The method comprises the stepsof administrating breast cancer patients with the tamoxifen and an Lnc-RNA molecule Lnc-DC inhibitor as well as a medicinal composition containing the tamoxifen and the Lnc-RNA molecule Lnc-DC inhibitor.

The invention discloses a molecule marker-PODN for early diagnosis of thyroid cancer. The research disclosed by the invention proves that compared with para-carcinoma tissue, the molecule marker-PODNhas the advantages that the mRNA expression level of a PODN gene in a patient suffering thyroid cancer is notably reduced. According to the relevance between the PODN gene and the thyroid cancer, anda reagent kit for diagnosis of the thyroid cancer can be prepared, and can be clinically and widely applied.

The invention discloses application of nano activated carbon sol in preparation of herpes virus therapeutics. The nano activated carbon sol is 1-100 nm in activated carbon particle size. The mass concentration of nano activated carbon in the nano carbon sol is less than or equal to 10%., and the surface of the nano activated carbon is modified with carboxyl groups. The application of the nano activated carbon sol in the preparation of therapeutics for treating skin diseases due to herpes virus provides significant effect, short process, high acting speed and zero recurrence after healing, great advance is made in medical science, and great clinical application value and practical significance are provided.

The invention belongs to the technical field of biomedical detection, and particularly relates to an ischemic retinopathy detection biomarker, a detection kit and application. The invention disclosesapplication of circRNA-Wdr37 in preparation of a diagnostic reagent for ischemic retinopathy and a diagnostic kit for ischemic retinopathy. Through high-throughput sequencing and quantitative PCR (Polymerase Chain Reaction) verification, the circRNA-Wdr37 is found to have remarkable correlation with ischemic retinopathy. The real-time fluorescence quantitative PCR technology is utilized, and the relative content of circRNA-Wdr37 in aqueous humor is detected; the detection biomarker and kit can be used for screening clinical ischemic retinopathy patients, and a theoretical basis is provided forearly intervention of ischemic retinopathy.

The invention discloses an anti-fatigue compound preparation, and a preparation method and anti-fatigue application thereof. Experimental results show that the compound preparation is capable of prolonging the loaded swimming time of middle-age and old mice, increasing the reservation of hepatic glycogen and reducing the contents of lactic acid and urea nitrogen through combined usage of natto andhorseradish tree leaves, and the effect of the combined usage of natto and horseradish tree leaves is obviously better than the effect of separate usage of natto and horseradish tree leaves. Moreover, the anti-fatigue compound preparation has the advantages of small dosage, safety, administration in both injecting and oral ways, etc., and has great health-care and clinic application value. The anti-fatigue compound preparation can be used for preparation of anti-fatigue health products or foodstuffs.

The invention discloses applications of a medicinal composition containing sisal hemp sapogenin in resisting fatigue. The medicinal composition is prepared from sisal hemp sapogenin and benserazide. Through the combined applications of sisal hemp sapogenin and benserazide, the experimental result shows that the loaded swimming time of mice can be prolonged, the storage of hepatic glycogen can be increased, the contents of lactic acid and urea nitrogen can be reduced, and the medicinal composition has the advantages that the use amount is small, the use is safe, and both injection and oral administration are available.

The invention discloses an anti-rhinitis traditional Chinese medicine composition which comprises the following traditional Chinese medicine raw materials: scutellaria baicalensis, ligusticum wallichii, magnolia flower, radix angelicae, bamboo juice, rhizoma acori graminei, thunberg fritillary bulb, platycodon grandiflorum, poria cocos, agastache rugosus and mint, the sum of the dosage of the scutellaria baicalensis and the dosage of the ligusticum wallichii is 2-4 times of the dosage of the bamboo juice, and preferably, the sum of the dosage of the scutellaria baicalensis and the dosage of the ligusticum wallichii is 3 times of the dosage of the bamboo juice. According to the anti-rhinitis traditional Chinese medicine composition provided by the invention, the compatibility design of a formula is reasonable, the monarch, minister, assistant and guide medication is scientific, the treatment purpose is single and clear, and the bamboo juice is innovatively used as a minister drug to be combined with a monarch drug containing a baical skullcap root-szechuan lovage rhizome pair to achieve the accidental treatment effect of cooperating with the monarch drug to synergistically relieve pain; moreover, the composition provided by the invention can also effectively treat allergic rhinitis, alleviates the irritation of the medicine to rhinitis patients, and has great clinical application value and market development potential.

The invention discloses a dry glucose test paper strip adopting Prussian blue nano-enzyme and a preparation method thereof, and belongs to the technical field of clinical diagnosis. According to the invention, Prussian blue nano-enzyme is adopted to replace natural horse radish peroxidase commonly used in a dry chemical test paper strip; the artificially synthesized Prussian blue nano material has the characteristic of catalyzing the reaction of peroxide and a substrate; and compared with a natural enzyme, the artificial enzyme has the advantages of being easy to store, convenient to prepare, low in cost, good in thermal stability and the like, can be industrially produced on a large scale, and can meet the requirements of clinical application.

The invention relates to a novel application of PTX-3 in medical detection. According to the invention, a series of scientific bioinformatics analysis methods are used as the screening method of the differential protein of the ovarian cancers and the normal ovarian tissues, the PTX-3 gene or PTX-3 protein is used as a marker for detecting or diagnosing the ovarian cancer and as an identification index of an ovarian cancer tumor, a junctional tumor and a normal ovarian epithelium for the first time, and the novel application of the PTX-3 gene or the PTX-3 protein as the ovarian cancer recurrence and metastasis monitoring marker is provided for the first time. The novel application of PTX-3 makes up for the deficiency of ovarian cancer recurrence and metastasis monitoring index deficiency, and has good clinical application value.